Reported by: Ijeoma G | Edited by: Oravbiere Osayomore Promise.
Greenlife Pharmaceuticals has issued an official clarification to address widespread misinformation circulating online regarding the packaging of its antimalarial medication, Lonart-DS. The company confirmed that the drug recently underwent an approved packaging update, which explains why both older and newer pack designs are currently available in the market. The clarification, released on May 21, 2026, comes after social media posts alleged that the updated packs were counterfeit or substandard, causing confusion and concern among consumers and healthcare professionals.
According to the statement, the packaging modification was carried out in compliance with regulatory requirements and with the full approval of the National Agency for Food and Drug Administration and Control (NAFDAC). Greenlife Pharmaceuticals emphasized that both the older and updated packs are authentic, effective, and safe for use. The company advised members of the public to purchase medications only from licensed and trusted pharmacies, and to always verify product authenticity using the mobile authentication short code provided on each pack. “We remain committed to public health safety and the dissemination of accurate health information,” the company said.
Lonart-DS is a widely used artemisinin-based combination therapy (ACT) for the treatment of uncomplicated malaria. Any confusion over its packaging could have posed risks to patient adherence and confidence in the drug. Greenlife’s swift response aims to allay fears and prevent the spread of false claims that could undermine malaria treatment efforts in Nigeria, where the disease remains a leading cause of morbidity and mortality. The company also urged healthcare providers and patients to report any suspicious products to NAFDAC or the nearest health authority.
This clarification follows a pattern of recurring misinformation about pharmaceutical products in Nigeria, where counterfeiters sometimes exploit packaging changes to introduce fake drugs. Greenlife’s proactive communication is seen as a model for transparency in the industry. The company reiterated its dedication to quality and patient safety, encouraging the public to rely on official channels for health information.
📩 Stone Reporters News | 🌍 stonereportersnews.com
✉️ info@stonereportersnews.com | 📘 Facebook: Stone Reporters News | 🐦 X (Twitter): @StoneReportNew | 📸 Instagram: @stonereportersnews
Add comment
Comments